Relationship Between Symptomatic and Functional Improvement and Remission in a Treatment Response to Stimulant Trial
| Autor: | Ann C. Childress, Robert J. Kupper, Earl Nordbrock, Greg Mattingly, Akwete L. Adjei, Margaret D. Weiss |
|---|---|
| Rok vydání: | 2018 |
| Předmět: |
Male
medicine.medical_specialty Treatment response Functional impairment Adolescent MPH-MLR medicine.medical_treatment 03 medical and health sciences 0302 clinical medicine Weiss Functional Impairment Rating Scale-Parent (WFIRS-P) Internal medicine mental disorders medicine Humans Learning 0501 psychology and cognitive sciences Pharmacology (medical) Child Randomized Controlled Trials as Topic business.industry 05 social sciences Wechsler Scales Original Articles attention-deficit/hyperactivity disorder (ADHD) Stimulant Psychiatry and Mental health Treatment Outcome functional impairment Attention Deficit Disorder with Hyperactivity Delayed-Action Preparations Pediatrics Perinatology and Child Health Methylphenidate Central Nervous System Stimulants Female business 030217 neurology & neurosurgery 050104 developmental & child psychology |
| Zdroj: | Journal of Child and Adolescent Psychopharmacology |
| ISSN: | 1557-8992 1044-5463 |
| DOI: | 10.1089/cap.2017.0166 |
| Popis: | Objective: To evaluate the relationship between symptom and functional improvement and remission in children and adolescents with attention-deficit/hyperactivity disorder (ADHD) enrolled in an 11-week open-label dose-optimization phase of an methylphenidate extended release (MPH-MLR) pivotal study. Methods: Assessments included the Weiss Functional Impairment Rating Scale-Parent (WFIRS-P) and ADHD Rating Scale, Fourth Edition (ADHD-RS-IV). Definitions included the following: symptom improvement (≥30% decrease in ADHD-RS-IV total score); symptom remission (ADHD-RS-IV total score ≤18); functional improvement (decrease in WFIRS-P total score ≥0.25 [minimally important difference]); and functional remission (WFIRS-P total score ≤0.65). Results: Two hundred children completed the open-label phase. At initial assessment, functional impairment was evident across all WFIRS-P domains and similar between children and adolescents. Those who were treatment naive had more functional impairment (WFIRS-P total: 0.82 vs. 0.70, p = 0.02). Significant improvements in all WFIRS-P domains were noted at open-label end (p |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|